New data presented at the European Congress on Obesity showed stronger results for 7.2 mg semaglutide than the standard Wegovy dose, while additional Novo Nordisk analyses found substantial weight loss in women across menopause stages and lower reported risks of migraine and depression | Read More in ynet – Culture